Concurrent Apatinib and Local Radiation Therapy for Advanced Gastric Cancer: A Case Report and Review of the Literature

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2017 Mar 2

PMID 28248891

Citations 8

Authors

Ming Zhang

Weiye Deng

Xiaoci Cao

Xiaoming Shi

Huanfen Zhao

Zheping Duan

Bonan Lv

Bin Liu

Affiliations

Soon will be listed here.

Abstract

Rationale: Apatinib is a novel anti-angiogenic agent targeting vascular endothelial growth factor receptor-2, which is effective in patients with chemotherapy-refractory gastric cancer. There are no reports of concurrent apatinib with local radiation therapy in elderly patients with advanced gastric cancer. PATIENT CONCERNS AND DIAGNOSES:: we present the first published report of a 70-year-old male patient with advanced gastric cancer who received concurrent apatinib and local radiation therapy after failure of oxaliplatin and S-1 chemotherapy.

Interventions And Outcomes: The patient received concurrent apatinib and local radiation therapy and was followed up 7 months after therapy without disease progress, 14 months later indicated extensive metastasis and this patient died of pulmonary infection.

Lessons: Elderly patients with advanced gastric cancer may benefit from concurrent apatinib with local radiation therapy when chemotherapy is not tolerated or successful. Further studies are needed to investigate the clinical outcomes and toxicities associated with concurrent apatinib and radiation therapy in gastric cancer.

Citing Articles

Advances in targeted therapy for human epidermal growth factor receptor 2 positive in advanced gastric cancer.

Jiang Y, Li W, Qiu Y, Yue M World J Gastrointest Oncol. 2024; 16(6):2318-2334.

PMID: 38994153 PMC: 11236256. DOI: 10.4251/wjgo.v16.i6.2318.

Tumor vessel normalization and immunotherapy in gastric cancer.

Yu X, He S, Shen J, Huang Q, Yang P, Huang L Ther Adv Med Oncol. 2022; 14:17588359221110176.

PMID: 35872968 PMC: 9297465. DOI: 10.1177/17588359221110176.

Apatinib inhibits the proliferation of gastric cancer cells via the AKT/GSK signaling pathway .

Chen Y, Chen N, Xu J, Wang X, Wei X, Tang C Aging (Albany NY). 2021; 13(16):20738-20747.

PMID: 34453028 PMC: 8436942. DOI: 10.18632/aging.203458.

Influence and mechanism of lung cavitation development on antiangiogenic therapy.

Jiang M, Zhang C, Liu D, Wang Y, Wang H, Li T Transl Lung Cancer Res. 2019; 8(4):500-512.

PMID: 31555522 PMC: 6749114. DOI: 10.21037/tlcr.2019.07.01.

Dual-Targeted Gold Nanoprism for Recognition of Early Apoptosis, Dual-Model Imaging and Precise Cancer Photothermal Therapy.

Zhang W, Ding X, Cheng H, Yin C, Yan J, Mou Z Theranostics. 2019; 9(19):5610-5625.

PMID: 31534506 PMC: 6735394. DOI: 10.7150/thno.34755.

References

Brown M . What causes the radiation gastrointestinal syndrome?: overview. Int J Radiat Oncol Biol Phys. 2008; 70(3):799-800. PMC: 2350186. DOI: 10.1016/j.ijrobp.2007.12.001. View

Hoffman K, Neville B, Mamon H, Kachnic L, Katz M, Earle C . Adjuvant therapy for elderly patients with resected gastric adenocarcinoma: population-based practices and treatment effectiveness. Cancer. 2011; 118(1):248-57. PMC: 3178711. DOI: 10.1002/cncr.26248. View

Brush J, Lipnick S, Phillips T, Sitko J, McDonald J, McBride W . Molecular mechanisms of late normal tissue injury. Semin Radiat Oncol. 2007; 17(2):121-30. DOI: 10.1016/j.semradonc.2006.11.008. View

Cunningham D, Okines A, Ashley S . Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2010; 362(9):858-9. DOI: 10.1056/NEJMc0911925. View

Ajani J, Buyse M, Lichinitser M, Gorbunova V, Bodoky G, Douillard J . Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. Eur J Cancer. 2013; 49(17):3616-24. DOI: 10.1016/j.ejca.2013.07.003. View

Folkman J . Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285(21):1182-6. DOI: 10.1056/NEJM197111182852108. View

Yoshida M, Wakabayashi G, Ishikawa H, Kameyama K, Shimazu M, Tanabe M . A possible defensive mechanism in the basal region of gastric mucosa and the healing of erosions. Clin Hemorheol Microcirc. 2004; 29(3-4):301-12. View

Potten C . Extreme sensitivity of some intestinal crypt cells to X and gamma irradiation. Nature. 1977; 269(5628):518-21. DOI: 10.1038/269518a0. View

Ferrara N, Kerbel R . Angiogenesis as a therapeutic target. Nature. 2005; 438(7070):967-74. DOI: 10.1038/nature04483. View

10.

Gurzu S, Kadar Z, Sugimura H, Bara T, Bara Jr T, Halmaciu I . Gastric cancer in young vs old Romanian patients: immunoprofile with emphasis on maspin and mena protein reactivity. APMIS. 2015; 123(3):223-33. DOI: 10.1111/apm.12347. View

11.

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

12.

Pollom E, Deng L, Pai R, Brown J, Giaccia A, Loo Jr B . Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2015; 92(3):568-76. PMC: 4816453. DOI: 10.1016/j.ijrobp.2015.02.016. View

13.

Spigel D, Hainsworth J, Yardley D, Raefsky E, Patton J, Peacock N . Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol. 2009; 28(1):43-8. DOI: 10.1200/JCO.2009.24.7353. View

14.

Lu S, Zhu Z . [Clinical and prognostic features of surgical treatment in gastric cancer in aged patients]. Zhonghua Wei Chang Wai Ke Za Zhi. 2016; 19(5):596-600. View

15.

Cheng A, Kang Y, Chen Z, Tsao C, Qin S, Kim J . Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2008; 10(1):25-34. DOI: 10.1016/S1470-2045(08)70285-7. View

16.

Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y . Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J Clin Oncol. 2016; 34(13):1448-54. DOI: 10.1200/JCO.2015.63.5995. View

17.

Zhang H . Apatinib for molecular targeted therapy in tumor. Drug Des Devel Ther. 2015; 9:6075-81. PMC: 4654530. DOI: 10.2147/DDDT.S97235. View

18.

Lordick F, Geinitz H, Theisen J, Sendler A, Sarbia M . Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases. Int J Radiat Oncol Biol Phys. 2006; 64(5):1295-8. DOI: 10.1016/j.ijrobp.2005.12.004. View

19.

Barney B, Markovic S, Laack N, Miller R, Sarkaria J, Macdonald O . Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT). Int J Radiat Oncol Biol Phys. 2013; 87(1):73-80. DOI: 10.1016/j.ijrobp.2013.05.012. View

20.

Geng R, Li J . Apatinib for the treatment of gastric cancer. Expert Opin Pharmacother. 2014; 16(1):117-22. DOI: 10.1517/14656566.2015.981526. View